[That this House expresses deep concern over the decision by Pfizer to award the contract for sole supplying of its pharmaceutical products to one wholesaler Unichem; is alarmed that this has created a de facto monopoly for Unichem in that pharmacies have no choice about who they deal with if they want to purchase Pfizer products; is concerned that whereas choice and competition have kept prices down this action will lead to a worse deal for local pharmacists, the NHS and ultimately the general public; is deeply alarmed that if Unichem had a Crisis in Its Distribution then other wholesalers would be unable to fill the gap left and thus people might not get the pharmaceutical products they absolutely rely on; and calls on the Office of Fair Trading and the Department of Health to investigate this issue with a focus on, respectively, the effect of this decision on unfair business practices and public health.